

TheraPEAK™ MSCGM™ Mesenchymal Stem Cell Growth Medium

Easy to use GMP medium for hMSC culture

Driven by new technologies and product platforms, scientific advancements in the cell therapy arena are being achieved with increasing frequency. Beyond their therapeutic promise, human mesenchymal stem cells (hMSCs) have become a model system widely used in stem cell research today. Their consistent expansion and viability are crucial to their therapeutic potential. Due to their ability to create an adaptive or innate immune response via interactions with lymphocytes, hMSC are becoming more ever present in clinical settings. With the increased concern for biological safety, lot-to-lot consistency and pre-qualification of FBS sources, serum-free growth medium has become a key element of stem cell culture.

As one of the largest cell therapy contract manufacturers in the world, Lonza recognizes the need for superior, reproducible, and reliable results during your cell culture process. TheraPEAK™ MSCGM™ Medium is an easy to use, high performing product produced in an FDA registered manufacturing site with an ISO 13485 certified quality management system. TheraPEAK™ MSCGM™ Medium maintains high viability of undifferentiated MSCs with rapid population doublings even in culture initiation.

Features and benefits

- Serum-free and regulatory friendly
- No need for attachment matrix to plate cells
- Optimized for multiple expansion of all types of hMSCs
- Supports multi-lineage differentiation
- Provided in BulletKit™ Format, includes basal medium and supplement
- Custom packaging available to meet scale up needs
- Can be used in small or large scale therapeutic applications

Optimal performance of your hMSCs

TheraPEAK™ MSCGM™ Medium Expansion




Figure 1. hMSCs grown in TheraPEAK™ MSCGM™ Medium exhibit better expansion over cells grown in serum-free MSC medium from Competitor I, as well as traditional DMEM with FBS. hMSCs were directly thawed into each respective medium and seeded at a density 2000 cells/cm² in T flasks. Cells were fed every 3 days and passaged at 95% confluence.

Place your order or contact us for further info

TheraPEAK™ MSCGM™ Mesenchymal Stem Cell Growth Medium BulletKit

Cat. no.	Description	Size
BEBP18-936	TheraPEAK™ MSCGM™ BulletKit™	1 L

You may as well be interested in our extensive portfolio of high quality, research grade primary stem cells and differentiation media. Contact our support teams or visit www.lonza.com/stemcells to learn more.

Cell characterization in serum-free media conditions

Cell surface marker	Positive (flow cytometry)	Negative (flow cytometry)
CD166	+	
CD105	+	
CD29	+	
CD44	+	
CD45		-
CD34		-
CD14		-

Table 1. Cell surface antigen expression of hMSCs grown in TheraPEAK™ MSCGM™ Medium.

Contact information

North America

Customer Service: + 1 800 638 8174 (toll free)
order.us@lonza.com
 Scientific Support: + 1 800 521 0390 (toll free)
scientific.support@lonza.com

Europe

Customer Service: + 32 87 321 611
order.europe@lonza.com
 Scientific Support: + 32 87 321 611
scientific.support.eu@lonza.com

International

Contact your local Lonza Distributor
 Customer Service: + 1 301 898 7025
 Fax: + 1 301 845 8291
scientific.support@lonza.com

Lonza Walkersville, Inc. – Walkersville, MD 21793

TheraPEAK™ Media Products are GMP produced and intended for research or further manufacturing use only but not for direct therapeutic use in humans. All trademarks belong to Lonza or its affiliates or to their respective third party owners. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights.